Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
56.09 USD -1.48% Intraday chart for Legend Biotech Corporation -3.69% -6.78%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Legend Biotech Files Mixed-Securities Shelf Registration MT
Genscript Biotech's US Unit Secures FDA Nod for Anti-Cancer Medication MT
UBS Adjusts Legend Biotech Price Target to $81 From $76, Maintains Buy Rating MT
Legend Biotech, Johnson & Johnson Cancer Therapy Wins FDA Advisory Panel Nod MT
Legend Biotech Corporation Announces CARVYKTI (Ciltacabtagene Autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma CI
US FDA panel unanimously backs expanded use of J&J's CAR-T therapy RE
US FDA staff flag safety concerns from J&J, Bristol's CAR-T therapies RE
Raymond James Starts Legend Biotech With Outperform Rating, $86 Price Target MT
Sector Update: Health Care Stocks Lean Lower Premarket Monday MT
Legend Biotech Corporation Announces Management Changes CI
Transcript : Legend Biotech Corporation, Q4 2023 Earnings Call, Mar 11, 2024
Legend Biotech Q4 Loss Narrows, Revenue Rises MT
Earnings Flash (LEGN) LEGEND BIOTECH CORPORATION Reports Q4 Revenue $79.5M MT
CPI, Tech Outlooks Cap Wall Street Pre-Bell; Asia, Europe Off MT
Futures Down Pre-Bell Ahead of Key Inflation Data; Asia Churns, Europe Falls MT
Legend Biotech Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Legend Biotech Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Legend Biotech Says European Panel Recommends Label Expansion of Carvykti for Treatment of Multiple Myeloma MT
Legend Biotech Corporation Announces Positive CHMP Opinion for CARVYKTI (Ciltacabtagene Autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Early Lines of Therapy CI
Genscript Biotech Unit Rakes in $159 Million in Sales for Myeloma Treatment; Shares Rise 4% MT
Genscript Biotech Unit to Submit More Data to European, US Authorities for Approval of Myeloma Drug MT
Legend Biotech Provides Update on U.S. FDA and EMA Applications for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel) in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma CI
US FDA requires 'boxed warning' for CAR-T cancer therapies RE
FDA REQUIRES GILEAD, JNJ, NOVARTIS, BRISTOL MYERS SQUIBB, 2SEVEN… RE
Chart Legend Biotech Corporation
More charts
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
56.09 USD
Average target price
86.43 USD
Spread / Average Target
+54.09%
Consensus
  1. Stock
  2. Equities
  3. Stock Legend Biotech Corporation - Nasdaq
  4. News Legend Biotech Corporation
  5. Legend Biotech : Morgan Stanley Adjusts Price Target on Legend Biotech to $51 From $50, Maintains Overweight Rating